Fine Foods & Pharmaceuticals N.T.M Past Earnings Performance
Past criteria checks 1/6
Fine Foods & Pharmaceuticals N.T.M's earnings have been declining at an average annual rate of -41.6%, while the Life Sciences industry saw earnings growing at 16% annually. Revenues have been growing at an average rate of 10.6% per year. Fine Foods & Pharmaceuticals N.T.M's return on equity is 2%, and it has net margins of 1.1%.
Key information
-41.6%
Earnings growth rate
-50.5%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 10.6% |
| Return on equity | 2.0% |
| Net Margin | 1.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Fine Foods & Pharmaceuticals N.T.M makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 247 | 3 | 46 | 0 |
| 31 Mar 24 | 252 | -4 | 46 | 0 |
| 31 Dec 23 | 252 | -4 | 45 | 0 |
| 30 Sep 23 | 240 | 1 | 43 | 0 |
| 30 Jun 23 | 234 | -5 | 42 | 0 |
| 31 Mar 23 | 222 | -4 | 40 | 0 |
| 31 Dec 22 | 207 | -10 | 39 | 0 |
| 30 Sep 22 | 203 | -10 | 39 | 0 |
| 30 Jun 22 | 196 | -1 | 38 | 0 |
| 31 Mar 22 | 194 | -6 | 36 | 0 |
| 31 Dec 21 | 195 | -1 | 35 | 0 |
| 30 Sep 21 | 198 | -1 | 35 | 0 |
| 30 Jun 21 | 200 | 2 | 34 | 0 |
| 31 Mar 21 | 190 | 13 | 33 | 0 |
| 31 Dec 20 | 177 | 13 | 31 | 0 |
| 30 Sep 20 | 162 | 8 | 28 | 0 |
| 30 Jun 20 | 153 | -1 | 27 | 0 |
| 31 Mar 20 | 157 | -2 | 28 | 0 |
| 31 Dec 19 | 161 | -3 | 28 | 0 |
| 30 Sep 19 | 157 | 8 | 29 | 0 |
| 30 Jun 19 | 153 | 9 | 29 | 0 |
| 31 Mar 19 | 147 | 9 | 28 | 0 |
| 31 Dec 18 | 140 | 9 | 26 | 0 |
Quality Earnings: 9S5 has a large one-off loss of €5.2M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 9S5 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9S5's earnings have declined by 41.6% per year over the past 5 years.
Accelerating Growth: 9S5 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 9S5 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.9%).
Return on Equity
High ROE: 9S5's Return on Equity (2%) is considered low.